TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy

MT Newswires Live06-03

TG Therapeutics' (TGTX) subcutaneous formulation of ublituximab showed "positive" pharmacokinetic, pharmacodynamic, safety, and tolerability data from a phase 1 clinical trial comparing the multiple sclerosis therapy to the drug's intravenous version, the company said Wednesday.

The high-concentration, low-volume subcutaneous version of ublituximab, the active agent in Briumvi, was also well-tolerated in the trial, which involved more than 100 patients, the company said.

The company expects to report data from a phase 3 trial of the self-administered therapy later this year or early next year and said it could advance toward potential approval in 2028 if successful.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment